<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723983</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-15-NP101-011</org_study_id>
    <nct_id>NCT00723983</nct_id>
  </id_info>
  <brief_title>Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period</brief_title>
  <acronym>NP101-011</acronym>
  <official_title>A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuPathe Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics of NP101 with a currently approved oral formulation of
      Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a
      non-migraine period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the pharmacokinetics of NP101 with a currently approved formulation of Imitrex in migraine subjects during an acute migraine attack and during a non-migraine period.</measure>
    <time_frame>PK samples at pre and 0.25, 0.5, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12 and 24 hours post each dose/period for Periods 1, 2, 3, and 4 [24 hour PK will not be done for Periods 5 and 6]</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject dosed with oral sumatriptan succinate during an acute migraine attack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject dosed with oral sumatriptan during a non-migraine period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3 and Period 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject dosed with NP101 during an acute migraine attack.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 4 and Period 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject dosed with NP101 study patch during a non-migraine period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan succinate</intervention_name>
    <description>Sumatriptan succinate 50 mg taken orally</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP101 Study Patch</intervention_name>
    <description>NP101 study patch 4 hour application</description>
    <arm_group_label>Period 3 and Period 6</arm_group_label>
    <arm_group_label>Period 4 and Period 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female subjects, between the ages of 18 to 65 years.

          -  Subjects with a diagnosis of migraine headache, with or without aura, as defined in
             the ICHD-II, and the diagnosis was made before the age of 50.

          -  The majority of a subject's headaches during a migraine attack are moderate to severe
             in intensity.

          -  Subject has history of regularly occuring migraines, accompanied by nausea or
             vomiting.

          -  Subject has at least one year history of migraine based upon subject testimony.

          -  Subject will be judged to be in good health, based upon the results of a medical
             history, physical examination, vital signs, ECG and laboratory profile.

          -  Subjects must voluntarily sign and date and Informed Consent agreement approved by an
             IRB.

          -  Subject must have a negative drug screen and re-screen.

          -  Female subjects of childbearing potential must have a negative pregnancy test at
             Screening and Re-Screening.

          -  Subject has two acceptable patch application sites.

        Exclusion Criteria:

          -  Subject has or plans to start stop, or change treatment (including dose change) of any
             medication within one month prior to the subject screening date and through the end of
             study.

          -  Subject has less than 2 migraines per month or subject has more than 15 headache
             days/month for any of the 3 months prior ot screening.

          -  Subject who has suspected or confirmed cardiovascular disease that contraindicates
             study participation.

          -  Subject has history of epilepsy or conditions associated with lower seizure threshold.

          -  Subject with Raynaud's disease.

          -  Subject with hemiplegic or basilar migraine.

          -  Subject with a current diagnosis of major depressive disorder.

          -  Subject who has taken non-triptan serotonergic drugs including SSRI's, SNRI, TCAs or
             MAOI's or preparations containing St. John's Wort within month prior to screening
             and/or is planning to start any of these medications during the study and through the
             End of Study Visit.

          -  Subject is unwilling to discontinue use of PD5 inhibitors (eg. Viagra, Levitra,
             Cialis) from screening through End of Study Visit.

          -  Subject with a history of significant allergy or hypersensitivity to any component of
             the NP101 study patch.

          -  Subject who has any generalized skin irritation or disease including eczema,
             psoriasis, melanoma, acne or contact dermatitis.

          -  Subject has a positive test result for hepatitis B, hepatitis C or is known to be HIV
             positive.

          -  Subjects with moderate or severe hepatic dysfunction defined as SGOT/AST or SGPT/ALT ≥
             2 times the upper limit of normal range, or alkaline phosphatase or total bilirubin ≥
             1.5 times the upper limit of normal range or if in the opinion of the investigator,
             the subject's history, physical examination or other laboratory tests suggest hepatic
             dysfunction.

          -  Female subjects who are pregnant, breast feeding, or if not of childbearing potential,
             is not using or is unwilling to use an effective form of contraception during the
             study and for a period of 30 days following final dosing.

          -  Subjects with a known history of tolerability issues with sumatriptan.

          -  Subject who is considered by the investigator or NuPathe to be an unsuitable candidate
             for this study.

          -  Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or
             dependence.

          -  Subject has participated in a clinical study within 30 days of Screening or is
             planning to participate in another clinical study.

          -  Subject has clinically significant abnormal labs, vital signs or ECG

          -  Subject is electrically sensitive or who has an implantable electronic device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerri L Wilks, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Clinic</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

